参考文献/References:
[1] Elstrom R,Guan L,Baker G,et al. Utility of FDG-PET scanning in lymphoma by WHO classification[J]. Blood,2003,101(10):3875-3876.
[2] Stumpe KD,Urbinelli M,Steinert HC,et al. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma:effectiveness and comparison with computed tomograp-hy[J]. Eur J Nucl Med,1998,25(7):721-728.
[3] Wirth A,Seymour JF,Hicks RJ,et al. Fluorine-18 fluorodeoxyg-lucose positron emission tomography,gallium-67 scintigraphy,and conventional staging for Hodgkin’s disease and non-Hodgkin’s lymphoma[J]. Am J Med,2002,112(4):262-268.
[4] Bar-Shalom R,Yefremov N,Haim N,et al. Camera-based FDG PET and 67Ga SPECT in evaluation of lymphoma:comparative study[J]. Radiology,2003,227(2):335-360.
[5] Rini JN,Nünez R,Nichols K,et al. Coincidence-detection FDG-PET versus gallium in children and young adults with newly diagnosed Hodgkin’s disease[J]. Pediatr Radiol,2005,35(2):169-178.
[6] Thill R,Neuerburg J,Fabry U,et al. Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma[J]. Nuklearmedizin,1997,36(7):234-239.
[7] Jerusalem G,Beguin Y,Najjar F,et al. Positron emission tomography (PET)with 18-fluorodeoxyglucose (18F-FDG)for the staging of low-grade non-Hodgkin’s lymphoma (NHL)[J]. Ann Oncol,2001,12(6):825-830.
[8] Delbeke D,Martin WH,Morgan DS,et al. 2-Deoxy-2-[-F-18-] fluoro-D-glucose imaging with positron emission tomography for initial staging of Hodgkin’s disease and lymphoma[J]. Mol Imaging Biol,2002,4(1):105-114.
[9] Partridge S,Timothy A,O’Doherty MJ,et al. 2-Fluorine-18-fluoro-2-deoxy-D-glucose positron emission tomography in the pretreatment staging of Hodgkin’s disease:influence on patient management in a single institution[J]. Ann Oncol,2000,11(10):1273-1279.
[10] Pakos EE,Fotopoulos AD,Ioannidis JP. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma:a meta-analysis[J]. J Nucl Med,2005,46(6):958-963.
[11] Castellucci P,Nanni C,Farsad M,et al. Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma:prevalence and scan interpretation[J]. Nucl Med Commun,2005,26(8):689-694.
[12] Spaepen K,Stroobants S,Dupont P,et al. Prognostic value of positron emission tomography (PET)with fluorine-18 fluorodeoxyg-lucose ([18F] FDG)after first-line chemotherapy in non-Hodgkin’s lymphoma:is[18F] FDG-PET a valid alternative to conventional diagnostic methods?[J]. J Clin Oncol,2001,19(2):414-419.
[13] Jerusalem G,Beguin Y,Fassotte MF,et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin’s disease[J],Ann Oncol,2003,14(1):123-130.
[14] Spaepen K,Stroobants S,Dupont P,et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma[J]. Ann Oncol,2002,13(9):1356-1363.
[15] Reinhardt MJ,Herkel C,Altehoefer C,et al. Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin’s and non-Hodgkin’s lymphoma patients:when do we really need FDG-PET?[J]. Ann Oncol,2005,16(9):1524-1529.
[16] Hutchings M,Mikhaeel NG,Fields PA,et al. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma[J],Ann Oncol,2005,16(7):1160-1168.
[17] Spaepen K,Stroobants S,Dupont P,et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation[J]. Blood,2003,102(1):53-59.
[18] Raanani P,Shasha Y,Perry C,et al. Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era?[J]. Ann Oncol,2006,17(1):117-122.
[19] Freudenberg LS,Antoch G,Schütt P,et al. FDG-PET/CT in re-staging of patients with lymphoma[J]. Eur J Nucl Med Mol Imaging,2004,31(3):325-329.
[20] Schaefer NG,Hany TF,Taverna C,et al. Non-Hodgkin lymphoma and Hodgkin disease:coregistered FDG PET and CT at staging and restaging-do we need contrast-enhanced CT?[J]. Radiology,2004,232(3):823-829.
[21] Wagner M,Seitz U,Buck A,et al. 3’-[18F]fluoro-3’-deoxythymi-dine([18F]-FLT)as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease[J]. Cancer Res,2003,63(10):2681-2687.
相似文献/References:
[1]何燕,苏晋,郑晓霞,等.P-糖蛋白抑制剂在PET显像中的应用研究[J].国际放射医学核医学杂志,2016,40(1):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
He Yan,Su Jin,ZhengXiaoxia,et al.Developing P-glycoprotein inhibitor marked by PET[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
[2]许飞,刘建军,黄钢,等.PET乏氧显像在预测肿瘤乏氧及指导临床治疗中的应用进展[J].国际放射医学核医学杂志,2016,40(1):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
Xu Fei,Liu Jianjun,Huang Gang,et al.The application of hypoxia imaging with PET in predicting tumor hypoxia and guiding clinical therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
[3]胡伟,赵军.小胶质细胞在AD炎性机制中的作用及其常见PET显像剂的应用进展[J].国际放射医学核医学杂志,2016,40(1):44.[doi:10.3760/cma.j.issn.1673-4114.2016.01.009]
Hu Wei,Zhao Jun.Microglia’s Alzheimer disease inflammatory mechanisms and progress of its common application in PET imaging agents[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):44.[doi:10.3760/cma.j.issn.1673-4114.2016.01.009]
[4]岳进,苏丽萍.全身MRI与PET/CT在淋巴瘤骨髓浸润诊断及预后中的作用[J].国际放射医学核医学杂志,2016,40(1):50.[doi:10.3760/cma.j.issn.1673-4114.2016.01.010]
Yue Jin,Su Lipin.Function of whole-body MRI and PET/CT in the diagnosis and prognosis of lymphoma with bone marrow infiltration[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):50.[doi:10.3760/cma.j.issn.1673-4114.2016.01.010]
[5]张莹莹,王振光,孔艳.PET/CT显像在肺间质纤维化中的应用进展[J].国际放射医学核医学杂志,2016,40(1):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
Zhang Yingying,Wang Zhenguang,Kong Yan.Application advancement on PET/CT in pulmonary interstitial fibrosis[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
[6]李海峰,张晓军,李云钢,等.国产模块LOOP环改良法合成11C-蛋氨酸[J].国际放射医学核医学杂志,2016,40(2):106.[doi:10.3760/cma.j.issn.1673-4114.2016.02.004]
Li Haifeng,Zhang Xiaojun,Li Yungang,et al.Synthesis of 11C-methionine on home-made module by the improved LOOP method[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):106.[doi:10.3760/cma.j.issn.1673-4114.2016.02.004]
[7]史文杰,孟召伟,谭建.基于Deauville标准探讨18F-FDG PET/CT在霍奇金淋巴瘤复发诊断中的应用价值[J].国际放射医学核医学杂志,2016,40(2):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
Shi Wenjie,Meng Zhaowei,Tan Jian.Value of 18F-FDG PET/CT on diagnosis of Hodgkin lymphoma recurrence using Deauville criterion[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
[8]李海峰,张晓军,张锦明.多巴胺转运蛋白显像剂11C-β-CFT在帕金森病中的应用研究[J].国际放射医学核医学杂志,2016,40(3):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
Li Haifeng,Zhang Xiaojun,Zhang Jinming.Review of the use of dopamine transporter imaging agent 11C-β-CFT for diagnosing Parkinson disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
[9]王朋,崔邦平,代文莉,等.18F-FDG PET/CT在前列腺癌中的应用进展[J].国际放射医学核医学杂志,2016,40(4):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
Wang Peng,Cui Bangping,Dai Wenli,et al.Progress in the application of 18F-FDG PET/CT in prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
[10]李菲,黄俊星,张俊.18F-FDG PET/CT在食管癌中的临床应用[J].国际放射医学核医学杂志,2016,40(4):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
Li Fei,Huang Junxing,Zhang Jun.The clinical application of 18F-FDG PET/CT in esophageal cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
[11]尤阳,轩昂,张杰,等.淋巴瘤患者大脑静息葡萄糖代谢改变[J].国际放射医学核医学杂志,2016,40(4):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
You Yang,Xuan Ang,Zhang Jie,et al.Changes in resting-state brain glucose metabolism in patients with lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
[12]胡娜,吴永港,肖立志,等.18F-FDG PET/CT代谢活性参数及其在淋巴瘤中的应用[J].国际放射医学核医学杂志,2015,39(4):342.[doi:10.3760/cma.j.issn.1673-4114.2015.04.015]
Hu Na,Wu Yonggang,Xiao Lizhi,et al.Metabolic parameters of 18F-FDG PET/CT and their application in lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):342.[doi:10.3760/cma.j.issn.1673-4114.2015.04.015]
[13]戴娜,吴翼伟.影像学技术在霍奇金淋巴瘤诊疗中的价值[J].国际放射医学核医学杂志,2014,38(2):117.[doi:10.3760/cma.j.issn.1673-4114.2014.02.011]
Dai Na,Wu Yiwei.The value of medical imaging methods in diagnosis and treatment of Hodgkin lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):117.[doi:10.3760/cma.j.issn.1673-4114.2014.02.011]
[14]杨希,党春江.泌尿系统原发性结外淋巴瘤的临床及影像学表现[J].国际放射医学核医学杂志,2013,37(4):230.[doi:10.3760/cma.j.issn.1673-4114.2013.04.010]
YANG Xi,DANG Chun-jiang.The clinical and imaging appearances of primary extranodal lymphoma of the urinary system[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):230.[doi:10.3760/cma.j.issn.1673-4114.2013.04.010]
[15]李艳梅,杨建伟,李鹏,等.单眼虹膜原发非霍奇金淋巴瘤18F-FDGPET/CT显像及疗效评价一例[J].国际放射医学核医学杂志,2013,37(5):326.[doi:10.3760/cma.j.issn.1673-4114.2013.05.017]
[16]萨日,赵红光,关锋,等.18F-FDG PET/CT在弥漫性大B细胞淋巴瘤疗效评价中的临床价值[J].国际放射医学核医学杂志,2013,37(1):9.[doi:10.3760/cma.j.issn.1673-4114.2013.01.003]
SA Ri,ZHAO Hong-guang,GUAN Feng,et al.Clinical value of 18F-FDG PET/CT in evaluation of curative effect on diffuse large B cell lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):9.[doi:10.3760/cma.j.issn.1673-4114.2013.01.003]
[17]李倩,刘建军.18F-FDG PET-CT评价淋巴瘤疗效及预后的价值[J].国际放射医学核医学杂志,2011,35(4):220.[doi:10.3760/cma.j.issn.1673-4114.2011.04.006]
LI Qian,LIU Jian-jun.The value of 18F-FDG PET-CT in lymphoma therapy evaluation and prognosis[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(6):220.[doi:10.3760/cma.j.issn.1673-4114.2011.04.006]
[18]秦文琼,高硕.PET/CT与临床预后因素在弥漫大B细胞淋巴瘤疗效评价及预后评估中的应用[J].国际放射医学核医学杂志,2017,41(6):437.[doi:10.3760/cma.j.issn.1673-4114.2017.06.010]
Qin Wenqiong,Gao Shuo.Application of PET/CT and clinical factors in the therapeutic and prognostic evaluation of diffuse large B cell lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(6):437.[doi:10.3760/cma.j.issn.1673-4114.2017.06.010]
[19]段钰,邓小虎,徐迟峰,等.面部原发性外周T细胞淋巴瘤-非特指型18F-FDG PET/CT显像一例[J].国际放射医学核医学杂志,2017,41(6):455.[doi:10.3760/cma.j.issn.1673-4114.2017.06.014]
[20]王剑杰,王雪鹃,蒲朝煜.恶性淋巴瘤的多模态显像研究进展[J].国际放射医学核医学杂志,2018,(4):363.[doi:10.3760/cma.j.issn.1673-4114.2018.04.014]
Wang Jianjie,Wang Xuejuan,Pu Chaoyu.The research progress of multimodal imaging in malignant lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(6):363.[doi:10.3760/cma.j.issn.1673-4114.2018.04.014]